• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline

Pipeline

May 10, 2021
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
HDT Bio

Gennova Biopharmaceuticals
RNA-based COVID-19 vaccine COVID-19 first patient dosed in phase 1/2 trial in India
Adagio Therapeutics ADG20 vaccine COVID-19 phase 2/3 trial initiated
Novavax NVX-CoV2373 vaccine COVID-10 in patients age 12 to 17 pediatric expansion of phase 3 clinical trial initiated
Other Trials and Actions
Genascence GNSC-001 osteoarthritis dosing of all patients in phase 1 trial complete
Neoleukin Therapeutics NL-201 advanced solid tumors phase 1 trial initiated
NervGen Pharma NVG-291 nerve damage first patient dosed in phase 1 trial
Vivace Therapeutics VT3989 refractory metastatic solid tumors first patient dosed in phase 1 trial in the U.S. and Australia
Repare Therapeutics RP-6306 PKMYT1 inhibitor-sensitive cancers first patient dosed in phase 1 trial
Landos Biopharma NX-13 ulcerative colitis first patient dosed in phase 1b trial
Vaxart oral tablet norovirus vaccine norovirus first patient enrolled in phase 1b boosting regimen trial
Cerecor CERC-007 adult-onset Still’s disease first patient dosed in phase 1b trial
Treadwell Therapeutics CFI-400945 PLK4 inhibitor in patients with leukemia first patient dosed in phase 1b/2 trial
Merus MCLA-129 advanced lung cancer and other solid tumors first patient treated in phase 1/2 clinical trial
Peptomyc OMO-103 lead compound advanced solid tumors first patient dosed in phase 1/2 trial
Carmot Therapeutics CT-868 treatment of overweight and obese patients with Type 2 diabetes IND for a phase 2 trial granted by the FDA
City of Hope mushroom powder tablets prostate-specific antigen levels recruiting begun in phase 2 trial
Tessa Therapeutics autologous CD30 CAR-T in relapsed/refractory cHL relapsed or refractory Hodgkins lymphoma enrollment of 12-patient cohort complete in phase 2 trial
Galmed Pharmaceuticals Aramchol nonalcoholic steatohepatitis and fibrosis IND for phase 3 trial granted by China’s National Medical Products Administration
Catalyst Biosciences MarzAA hemophilia A or B with inhibitors first patient dosed in phase 3 trial
Isofol Medical Arfolitixorin first-line metastatic colorectal cancer recruiting complete in global phase 3 trial
ObSeva Yslty moderate-to-severe endometriosis-associated pain enrollment complete in phase 3 trial
Praxis Precision Medicines PRAX-562 SCN2A development and epileptic encephalopathy Orphan Drug designation granted by the FDA
Cerapedics P-15L bone graft in cases of degenerative disc disease Breakthrough Device designation awarded by the FDA
AstraZeneca Farxiga (dapagliflozin) oral tablets kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression approved by the FDA
Chiesi Global Rare Diseases Ferriprox (deferiprone) transfusional iron overload caused by sickle cell disease or other anemias in adults and children ages three years and older approved by the FDA
Merck Keytruda in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma approved by the FDA

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing